(Q37268893)

19 August 2017

1 reference

title

Medical therapy of pituitary adenomas: effects on tumor shrinkage (English)

1 reference

19 August 2017

1

Annamaria Colao

1 reference

19 August 2017

6

Gaetano Lombardi

1 reference

19 August 2017

2

Rosario Pivonello

1 reference

19 August 2017

4

Silvia Savastano

1 reference

19 August 2017

5

Ludovica F S Grasso

1 reference

19 August 2017

Carolina Di Somma

3

1 reference

19 August 2017

1 June 2009

1 reference

Reviews in Endocrine and Metabolic Disorders

19 August 2017

1 reference

19 August 2017

10

1 reference

19 August 2017

111-123

1 reference

19 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s11154-008-9107-z

19 August 2017

0 references

cites work

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

Octreotide treatment does not affect the size of most non-functioning pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-008-9107-Z

Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly

21 January 2018

1 reference

12 December 2020

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

1 reference

12 December 2020

In VivoDetection of Somatostatin Receptors in Patients with Functionless Pituitary Adenomas by Means of a Radioiodinated Analog of Somatostatin ([123I]SDZ 204–090)*

1 reference

12 December 2020

1 reference

12 December 2020

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

1 reference

12 December 2020

Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma

1 reference

12 December 2020

Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage

1 reference

12 December 2020

Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?

1 reference

12 December 2020

Antiangiogenic effects of somatostatin analogues

1 reference

12 December 2020

Alternative splicing directs the expression of two D2 dopamine receptor isoforms.

1 reference

12 December 2020

Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy

1 reference

12 December 2020

Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas

1 reference

12 December 2020

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

1 reference

12 December 2020

Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment

1 reference

12 December 2020

Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide

1 reference

12 December 2020

1 reference

12 December 2020

Dopamine agonists and pituitary tumor shrinkage

1 reference

12 December 2020

Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature

1 reference

12 December 2020

Predictors and rates of treatment-resistant tumor growth in acromegaly.

1 reference

12 December 2020

Cabergoline plus lanreotide for ectopic Cushing's syndrome

1 reference

12 December 2020

SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas

1 reference

12 December 2020

Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.

1 reference

12 December 2020

Dopamine receptor expression and function in corticotroph ectopic tumors.

1 reference

12 December 2020

Acromegaly. Recognition and treatment

1 reference

12 December 2020

Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors

1 reference

12 December 2020

Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.

1 reference

12 December 2020

Octreotide long-acting release (LAR): a review of its use in the management of acromegaly

1 reference

12 December 2020

Effect of different dopaminergic agents in the treatment of acromegaly

1 reference

12 December 2020

Somatostatin receptor subtype expression in human tumors

1 reference

12 December 2020

Dopamine receptor expression and function in corticotroph pituitary tumors

1 reference

12 December 2020

Morphological effects of octreotide on growth hormone-producing pituitary adenomas

1 reference

12 December 2020

Physiology of somatostatin receptors

1 reference

12 December 2020

Reduced size of a hormonally silent pituitary adenoma during treatment with CV 205-502, a new dopamine agonist mainly stimulating D2 receptors

1 reference

12 December 2020

Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly

1 reference

12 December 2020

Somatostatin analogs in acromegaly

1 reference

12 December 2020

Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours

1 reference

12 December 2020

Complete remission of Nelson's syndrome after 1-year treatment with cabergoline

1 reference

12 December 2020

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly.

1 reference

12 December 2020

D2 dopaminergic receptors: normal and abnormal transduction mechanisms

1 reference

12 December 2020

Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient

1 reference

12 December 2020

Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy

1 reference

12 December 2020

Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat

1 reference

12 December 2020

Dopamine receptor agonists for treating prolactinomas

1 reference

12 December 2020

Cabergoline decreases somatotroph adenoma size: a case report

1 reference

12 December 2020

TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide

1 reference

12 December 2020

Specific somatostatin receptors on human pituitary adenoma cell membranes

1 reference

12 December 2020

Somatostatin Analogs in Treatment of Non-Growth Hormone-Secreting Pituitary Adenomas

1 reference

12 December 2020

Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine.

1 reference

12 December 2020

New medical approaches in pituitary adenomas

1 reference

12 December 2020

Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995)

1 reference

12 December 2020

Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas

1 reference

12 December 2020

Thyrotropin-secreting pituitary tumors

1 reference

12 December 2020

A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly

1 reference

12 December 2020

Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas

1 reference

12 December 2020

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

1 reference

12 December 2020

Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide

1 reference

12 December 2020

In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas

1 reference

12 December 2020

Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.

1 reference

12 December 2020

Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial

1 reference

12 December 2020

Cabergoline in the treatment of acromegaly: a study in 64 patients.

1 reference

12 December 2020

Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia

1 reference

12 December 2020

In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide

1 reference

12 December 2020

Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas

1 reference

12 December 2020

Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors

1 reference

12 December 2020

Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients

1 reference

12 December 2020

Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors

1 reference

12 December 2020

Signal transduction of somatostatin receptors negatively controlling cell proliferation.

1 reference

12 December 2020

A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group

1 reference

12 December 2020

The medical treatment of Cushing's syndrome

1 reference

12 December 2020

Guidelines for acromegaly management

1 reference

12 December 2020

Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma

1 reference

12 December 2020

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

1 reference

12 December 2020

Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients

1 reference

12 December 2020

Somatostatin receptor subtypes: targeting functional and therapeutic specificity.

1 reference

12 December 2020

Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients

1 reference

12 December 2020

Dopamine receptors: from structure to function

1 reference

12 December 2020

Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy

1 reference

12 December 2020

Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro

1 reference

12 December 2020

Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline

1 reference

12 December 2020

Somatostatin Regulation of Glycoprotein Hormone and Free Subunit Secretion in Clinically Nonfunctioning and Somatotroph Adenomasin Vitro*

1 reference

12 December 2020

Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas

1 reference

12 December 2020

Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males

1 reference

12 December 2020

Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses

1 reference

12 December 2020

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

12 December 2020

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

1 reference

12 December 2020

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients

1 reference

12 December 2020

Advances in the treatment of prolactinomas

1 reference

12 December 2020

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S11154-008-9107-Z

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18791829